Clinical Trial Update: Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C [Phase 1]

View source ↗

Summary

Phase 1 study in Chinese participants with elevated LDL-C evaluated pharmacokinetics, pharmacodynamics, safety and tolerability of Inclisiran and is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hyperlipidemia | Phase 1 | Status: COMPLETED